(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 November 2009 (19.11.2009)

PCT

(10) International Publication Number
WO 2009/138393 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *A61P 25/00* (2006.01)
A61K 31/44 (2006.01)

(21) International Application Number:
PCT/EP2009/055700

(22) International Filing Date:
12 May 2009 (12.05.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0808747.0 14 May 2008 (14.05.2008) GB

(71) Applicant *(for all designated States except US)*: **GLAXO WELLCOME MANUFACTURING PTE LTD** [SG/SG]; 1 Pioneer Sector 1, Jurong, 628413 (SG).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALVARO, Giuseppe** [IT/IT]; GlaxoSmithKline, via Alessandro Fleming 2, I-37135 Verona (IT). **MARASCO, Agostino** [IT/IT]; GlaxoSmithKline, via Alessandro Fleming 2, I-37135 Verona (IT).

(74) Agents: **PEZZOLI, Anna** et al.; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS



(I)

(57) Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C_{1-4} alkyl useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.

WO 2009/138393 A1